Ovarian cancer remains a leading cause of gynecological cancer-related mortality. Although the standard therapy is usually effective at first, the development of multidrug resistance (MDR) significantly limits the efficacy of the treatment. Topotecan (TOP) is a drug commonly used in second-line therapy. However, the cancer cells eventually become immune to its cytotoxic effect, as they start to produce ATP-binding cassette (ABC) transporters, proteins facilitating drug removal. Breast cancer resistance protein (BCRP) is one such protein, and TOP is its known substrate. Vismodegib, a Sonic Hedgehog pathway (Shh) inhibitor, has demonstrated potential anticancer activity in various malignancies. This study aims to evaluate the effects of Vismodegib treatment on both topotecan-sensitive and -resistant ovarian cancer cell lines, cultured in two-dimensional (2D) and three-dimensional (3D) conditions, as well as the potential of Vismodegib treatment to reverse the acquired drug resistance. Our results suggest that Vismodegib re-sensitizes TOP-resistant cells in both 2D and 3D models. However, further research is needed to evaluate its usefulness in ovarian cancer treatment.
Stasiak et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: